Jesper Lau, PhDVice President, Protein and Peptide Chemistry at Novo Nordisk A/SSpeaker
Agenda Sessions
Discovery and Development of Semaglutide – The First Orally Available GLP-1 Peptide for Treatment of Type 2 Diabetes
On Demand - For MembersView Session